Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axitinib intravitreal implant - Ocular Therapeutix

Next Previous
Drug Profile

Axitinib intravitreal implant - Ocular Therapeutix

Alternative Names: AXPAXLI; OTX-TKI; Tyrosine kinase inhibitor implant

Latest Information Update: 12 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocular Therapeutix
  • Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diabetic macular oedema; Wet age-related macular degeneration
  • Phase I Diabetic retinopathy
  • No development reported Retinal vein occlusion

Most Recent Events

  • 08 Dec 2025 Ocular Therapeutix plans to files an NDA application with the US Food and Drug Administration (FDA) in the US for Wet age-related macular degeneration followed by one year results of SOL-1 phase III trial is first quarter of 2026
  • 24 Nov 2025 Phase-III clinical trials in Diabetic macular oedema in USA (Intravitreous) (NCT07235085)
  • 30 Sep 2025 Adverse events data from a phase III SOL-1 trial in Wet age-related macular degeneration released by Ocular Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top